Medtronic is upping the ante in a patent dispute with competitor Axonics Inc. that has already lasted more than four years. The dispute centers on Medtronic’s InterStim device, an implanted ...

DUBLIN, Feb. 22, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it received approval from the U.S. Food and Drug Administration (FDA) for ...

The FDA has approved Medtronic plc's (NYSE: MDT) InterStim X, the next generation of the InterStim portfolio's recharge-free device. InterStim systems deliver sacral neuromodulation (SNM) therapy.

(WNDU) - It’s a taboo topic that nobody talks about. But 1 in 6 Americans suffer with either urinary or bowel incontinence. That’s more than the number of people with Alzheimer’s, diabetes, or breast ...

DUBLIN - July 17, 2017 - Medtronic plc (MDT) today announced that the InterStim(TM) system, which provides sacral neuromodulation therapy, offers sustained long-term efficacy and quality of life ...

Smaller, Rechargeable Device Will Provide More Choices for Patients Suffering with Bladder and Bowel Control Issues SureScan™ MRI Leads Will Provide Full-Body MRI Conditional Labeling The rechargeable ...

Medtronic Inc. (NYSE:MDT) got a thumbs up for its InterStim sacral nerve stimulation product’s clinical trials. The Minneapolis, Minn.-based device giant published new data on its InterStim device, ...

A successful treatment for bladder incontinence has a new twist that makes it accessible to more people. Bladder incontinence is a problem that impacts about 37 million people. One in six Americans ...

Stimguard LLC will begin enrollment for a head-to-head study of its Chronic Affarent Nerve Stimulator (CAN-stim) against Medtronic plc's gold standard Interstim device in treatment of urgency urinary ...

Medtronic has submitted for FDA approval a new, rechargeable version of its 20-year-old sacral neuromodulation implant, designed to treat bowel dysfunction, overactive bladder and urinary incontinence ...